Antibody-dependent cell cytotoxicity (ADCC) is critical in monoclonal antibody (mAb)-mediated cancer therapy. We recently showed that a tumor-specific mAb in combination with cyclophosphamide inhibited tumor cell growth and induced ADCC-synapses between tumor and effector cells in vivo, opening perspectives to enhance anti-tumor responses by manipulating the immune system.
No takes yet. Share an insight, caveat, or question.
Hubert et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: